Clinical TrialApr 27, 2026, 04:06 PM
GPCR to present positive aleniglipron Phase 2b data at ADA 2026
AI Summary
Structure Therapeutics Inc. announced multiple presentations at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026. Key presentations include an oral presentation on the ACCESS Phase 2b clinical trial of aleniglipron, an oral small molecule GLP-1RA, demonstrating meaningful weight reductions in people with obesity and overweight. Additional presentations will cover safety, tolerability, and efficacy of aleniglipron in the ACCESS II trial, exploring lower starting doses for improved GI tolerability, and combination treatment data with ACCG-2671 showing additional weight loss.
Key Highlights
- Oral presentation on ACCESS Phase 2b clinical trial of aleniglipron, an oral GLP-1RA.
- Aleniglipron demonstrated meaningful weight reductions in people with obesity and overweight.
- Presentation on safety, tolerability, and efficacy of aleniglipron up to 240 mg in ACCESS II trial.
- Data on exploring a lower starting dose of aleniglipron to improve GI tolerability.
- Combination treatment of aleniglipron and ACCG-2671 showed additional weight loss in obese NHPs.
- Presentations scheduled for June 5-8, 2026, at the ADA 86th Scientific Sessions.
Price Impact
More from GPCR